HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Dramatic inhibition of retinal and choroidal neovascularization by oral administration of a kinase inhibitor.

Abstract
The most common cause of new blindness in young patients is retinal neovascularization, and in the elderly is choroidal neovascularization. Therefore, there has been a great deal of attention focused on the development of new treatments for these disease processes. Previous studies have demonstrated partial inhibition of retinal neovascularization in animal models using antagonists of vascular endothelial growth factor or other signaling molecules implicated in the angiogenesis cascade. These studies have indicated potential for drug treatment, but have left many questions unanswered. Is it possible to completely inhibit retinal neovascularization using drug treatment with a mode of administration that is feasible to use in patients? Do agents that inhibit retinal neovascularization have any effect on choroidal neovascularization? In this study, we demonstrate complete inhibition of retinal neovascularization in mice with oxygen-induced ischemic retinopathy by oral administration of a partially selective kinase inhibitor that blocks several members of the protein kinase C family, along with vascular endothelial growth factor and platelet-derived growth factor receptor tyrosine kinases. The drug also blocks normal vascularization of the retina during development but has no identifiable adverse effects on mature retinal vessels. In addition, the kinase inhibitor causes dramatic inhibition of choroidal neovascularization in a laser-induced murine model. These data provide proof of concept that pharmacological treatment is a viable approach for therapy of both retinal and choroidal neovascularization.
AuthorsM S Seo, N Kwak, H Ozaki, H Yamada, N Okamoto, E Yamada, D Fabbro, F Hofmann, J M Wood, P A Campochiaro
JournalThe American journal of pathology (Am J Pathol) Vol. 154 Issue 6 Pg. 1743-53 (Jun 1999) ISSN: 0002-9440 [Print] United States
PMID10362799 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S.)
Chemical References
  • Enzyme Inhibitors
  • Protein-Tyrosine Kinases
  • Protein Kinase C
  • Staurosporine
  • midostaurin
Topics
  • Administration, Oral
  • Animals
  • Choroidal Neovascularization (prevention & control)
  • Dose-Response Relationship, Drug
  • Enzyme Inhibitors (administration & dosage, pharmacology)
  • Female
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Protein Kinase C (antagonists & inhibitors)
  • Protein-Tyrosine Kinases (antagonists & inhibitors)
  • Retina (drug effects, growth & development)
  • Retinal Neovascularization (prevention & control)
  • Retinal Vessels (drug effects)
  • Staurosporine (administration & dosage, analogs & derivatives, pharmacology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: